GLP‑1 RAs vs SGLT2i on (Micro)albuminuria
In type 2 diabetes with kidney involvement, both GLP‑1 receptor agonists (GLP‑1 RAs) and SGLT2 inhibitors (SGLT2i) improve albuminuria, but their relative strength and focus differ across studies.
Overall Renal and Albuminuria Effects
- Network meta‑analyses and reviews show both classes reduce renal events, but SGLT2i generally give stronger protection against kidney function decline, whereas GLP‑1 RAs show particularly strong effects on albuminuria (mostly macro‑ or micro‑albuminuria) (Kawai et al., 2021; Bae, 2025; Nincevic et al., 2019; Santos et al., 2025).
- One meta‑analysis in patients with and without albuminuria found SGLT2i had lower renal risk than GLP‑1 RAs overall (RR ~0.75 with albuminuria, 0.59 without) (Kawai et al., 2021).
Direct Comparisons: Albuminuria / Microalbuminuria
Incident / Progression to Macroalbuminuria
- Real‑world and trial‑based comparisons pooling studies did not find a clear difference in incident macroalbuminuria between GLP‑1 RAs and SGLT2i (pooled HR 1.02, 95% CI 0.82–1.27) (Fishkin et al., 2025).
- In a large matched cohort, change in albuminuria was similar between SGLT2i and GLP‑1 RA overall; in patients without CKD, new macroalbuminuria numerically favored GLP‑1 RA but attenuated after requiring confirmatory tests (Fadini et al., 2024).
- Another population‑based study showed SGLT2i users had a trend to lower incident macroalbuminuria than GLP‑1 RA (HR 0.74, p=0.05) (Lui et al., 2022).
Regression / Improvement of Albuminuria
- Long‑term observational data: SGLT2i were associated with greater albuminuria regression than GLP‑1 RAs (HR 1.72) (Sohn et al., 2024).
- In advanced DKD (stage 3–4), a small prospective cohort found SGLT2i produced more albuminuria reduction in stage 3 CKD, whereas GLP‑1 RAs preserved eGFR better in stage 4 (Aledan et al., 2023).
Summary Table: Albuminuria‑Related Outcomes
| Outcome vs other class | Favored | Citations |
|---|---|---|
| Overall renal risk (incl. albuminuria) | SGLT2i | (Kawai et al., 2021; Lui et al., 2022; Sohn et al., 2024) |
| Incident macroalbuminuria | No clear difference | (Lui et al., 2022; Fishkin et al., 2025; Fadini et al., 2024) |
| Albuminuria regression | SGLT2i | (Sohn et al., 2024; Aledan et al., 2023) |
| Albuminuria progression vs basal insulin | GLP‑1 RA better than insulin | (Schechter et al., 2023) |
Figure 1: Comparative albuminuria effects of GLP-1 RA and SGLT2i
Mechanistic/Clinical Takeaway
- GLP‑1 RAs: Strong anti‑inflammatory and metabolic effects, consistently reduce albuminuria vs older agents, but may be somewhat weaker than SGLT2i on “hard” kidney outcomes (Bae, 2025; Nincevic et al., 2019; Schechter et al., 2023).
- SGLT2i: More potent in preserving eGFR and composite kidney outcomes, with at least comparable, and in several studies better, albuminuria regression (Kawai et al., 2021; Lui et al., 2022; Sohn et al., 2024; Fadini et al., 2024; Santos et al., 2025).
Conclusion
Both GLP‑1 RAs and SGLT2i improve micro/macroalbuminuria, but when directly or indirectly compared, SGLT2i tend to provide equal or greater reduction in albuminuria and clearly better protection against kidney function loss, while GLP‑1 RAs still offer meaningful albuminuria benefits, especially compared with older glucose‑lowering drugs.
These search results were found and analyzed using Consensus, an AI-powered search engine for research. Try it at https://consensus.app. © 2026 Consensus NLP, Inc. Personal, non-commercial use only; redistribution requires copyright holders’ consent.
References
Aledan, H., Saadi, S., & Rasheed, J. (2023). Evaluation of effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on estimated glomerular filtration rate, albuminuria and weight in diabetic kidney disease: A prospective cohort study. **.
Bae, J. (2025). SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application. Diabetes & Metabolism Journal, 49, 386 - 402. https://doi.org/10.4093/dmj.2025.0220
Fadini, G., Longato, E., Morieri, M., Bonora, E., Consoli, A., Fattor, B., Rigato, M., Turchi, F., Del Prato, S., Avogaro, A., & Solini, A. (2024). Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care. Diabetologia, 67, 2585 - 2597. https://doi.org/10.1007/s00125-024-06251-z
Fishkin, A., Rozenberg, A., Schechter, M., Sehtman-Shachar, D., Aharon-Hananel, G., Leibowitz, G., Yanuv, I., & Mosenzon, O. (2025). Kidney Outcomes With Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Glucose‐Lowering Agents in People With Type 2 Diabetes: A Systematic Review and Meta‐Analysis of Real‐World Data. Diabetes/Metabolism Research and Reviews, 41. https://doi.org/10.1002/dmrr.70066
Kawai, Y., Uneda, K., Yamada, T., Kinguchi, S., Kobayashi, K., Azushima, K., Kanaoka, T., Toya, Y., Wakui, H., & Tamura, K. (2021). Comparison of effects of SGLT-2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus patients with/without albuminuria: a systematic review and network meta-analysis.. Diabetes research and clinical practice, 109146. https://doi.org/10.1016/j.diabres.2021.109146
Lui, D., Au, I., Tang, E., Cheung, C., Lee, C., Woo, Y., Wu, T., Tan, K., & Wong, C. (2022). Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: A real-world population-based analysis. eClinicalMedicine, 50. https://doi.org/10.1016/j.eclinm.2022.101510
Nincevic, V., Kolarić, T., Roguljić, H., Kizivat, T., Smolić, M., & Ćurčić, I. (2019). Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes. International Journal of Molecular Sciences, 20. https://doi.org/10.3390/ijms20235831
Santos, G., Rocha, G., Calmon, M., Lemos, F., Luis, G., Luz, M., Pinheiro, S., Botelho, A., & Melo, F. (2025). Beyond glycemic control: Roles for sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in diabetic kidney disease. World Journal of Diabetes, 16. https://doi.org/10.4239/wjd.v16.i6.104706
Schechter, M., Cohen, M., Fishkin, A., Rozenberg, A., Yanuv, I., Sehtman-Shachar, D., Chodick, G., Clark, A., Abrahamsen, T., Lawson, J., Karasik, A., & Mosenzon, O. (2023). Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence. Cardiovascular Diabetology, 22. https://doi.org/10.1186/s12933-023-01829-0
Sohn, M., Nam, S., Nauck, M., & Lim, S. (2024). Long-term comparison of renal and metabolic outcomes after sodium–glucose co-transporter 2 inhibitor or glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes. BMC Medicine, 22. https://doi.org/10.1186/s12916-024-03483-z
@resident